Shibo Jiang, MD, PhD
Researches in the Laboratory of Viral Immunology are focused on the development of antiviral therapeutic agents and vaccines for the treatment and prevention of HIV infection/AIDS and other emerging and remerging infectious diseases caused by severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), and influenza viruses, as well as the blood transfusion-related viruses, including zika virus (ZIKV) and West Nile virus (WNV).
Dr. Shibo Jiang is a pioneer in the field of viral fusion/entry inhibitors. His research focuses on development of therapeutics/vaccines against HIV, SARS-CoV, MERS-CoV, and avian influenza viruses. He has published 311 peer-reviewed papers, awarded 18 US patents, and served as editorial board members for 8 journals.
Phone: +1 (212) 570-3058